The company's technology platform was developed to meet the growing demand for animal-free media components in the biopharma industry.

It will be the first dedicated, animal-free peptone, and protein hydrolysate manufacturing facility in the U.S. The plant aims to meet the rapidly growing demand for materials used to manufacture biologics. Construction on the new facility is expected to being in the spring of 2021.

Scientists achieve milestone in animal-free production of biologics
For the first time, scientists have successfully produced sugar-based biologic molecules utilizing bacteria, without the need for animal products. The...

New synthetic biology approach may improve delivery of programmable medicines
Programmable medicines that can be controlled by synthetic genetic components are not yet a clinical reality. But synthetic components can now be reconfigured...

Could heparin-based therapies be a viable treatment for COVID-19?
Researchers have identified a novel approach to treating SARS-CoV-2 infection, spurred by a new understanding of viral attachment involving a heparan...